tetano
Editor, Senior Moderator
Ann Biol Clin (Paris)
. 2020 Jun 1;78(3):269-277.
doi: 10.1684/abc.2020.1563.
SFBC Working Group "Biochemical Markers of COVID-19"
Marie-Christine Beauvieux[SUP] 1 [/SUP], Annie M B?rard[SUP] 2 [/SUP], Isabelle Aimone-Gastin[SUP] 3 [/SUP], Fran?oise Barb?[SUP] 4 [/SUP], Yann Barguil[SUP] 5 [/SUP], Delphine Collin-Chavagnac[SUP] 6 [/SUP], Herv? Delacour[SUP] 7 [/SUP], C?line Delevall?e[SUP] 8 [/SUP], Val?rie Nivet-Antoine[SUP] 9 [/SUP], Katell Peoc'h[SUP] 10 [/SUP], Carole Poupon[SUP] 11 [/SUP], Fran?ois Schmitt[SUP] 12 [/SUP], Laurence Pi?roni[SUP] 13 [/SUP], Vincent Sapin[SUP] 14 [/SUP], Membres du Groupe de travail SFBC ? Marqueurs biochimiques de COVID-19 ?; Sous-groupe Priv?s; Sous-groupe Outre-Mer (OM)/francophonie; Sous-groupe CH; Sous-groupe H?pitaux d’instruction des arm?es (HIA); Sous-groupe CHU Nord-Est; Sous-groupe CHU Ouest; Sous-groupe CHU Assistance publique-H?pitaux de Paris (AP-HP); Sous-groupe CHU Sud; Sous-groupe CHU Auvergne Rh?ne-Alpes-Bourgogne Franche-Comt? (ARA-BFC)
Collaborators, Affiliations
Abstract
The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14[SUP]th[/SUP], the start of the planned containment exit from May 11[SUP]th[/SUP]. Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions.
Keywords: COVID-19; biological markers; medical biology.
. 2020 Jun 1;78(3):269-277.
doi: 10.1684/abc.2020.1563.
SFBC Working Group "Biochemical Markers of COVID-19"
Marie-Christine Beauvieux[SUP] 1 [/SUP], Annie M B?rard[SUP] 2 [/SUP], Isabelle Aimone-Gastin[SUP] 3 [/SUP], Fran?oise Barb?[SUP] 4 [/SUP], Yann Barguil[SUP] 5 [/SUP], Delphine Collin-Chavagnac[SUP] 6 [/SUP], Herv? Delacour[SUP] 7 [/SUP], C?line Delevall?e[SUP] 8 [/SUP], Val?rie Nivet-Antoine[SUP] 9 [/SUP], Katell Peoc'h[SUP] 10 [/SUP], Carole Poupon[SUP] 11 [/SUP], Fran?ois Schmitt[SUP] 12 [/SUP], Laurence Pi?roni[SUP] 13 [/SUP], Vincent Sapin[SUP] 14 [/SUP], Membres du Groupe de travail SFBC ? Marqueurs biochimiques de COVID-19 ?; Sous-groupe Priv?s; Sous-groupe Outre-Mer (OM)/francophonie; Sous-groupe CH; Sous-groupe H?pitaux d’instruction des arm?es (HIA); Sous-groupe CHU Nord-Est; Sous-groupe CHU Ouest; Sous-groupe CHU Assistance publique-H?pitaux de Paris (AP-HP); Sous-groupe CHU Sud; Sous-groupe CHU Auvergne Rh?ne-Alpes-Bourgogne Franche-Comt? (ARA-BFC)
Collaborators, Affiliations
- PMID: 32540814
- DOI: 10.1684/abc.2020.1563
Abstract
The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14[SUP]th[/SUP], the start of the planned containment exit from May 11[SUP]th[/SUP]. Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions.
Keywords: COVID-19; biological markers; medical biology.